No abstract available
MeSH terms
-
Animals
-
Antipsychotic Agents / adverse effects*
-
Dibenzothiazepines / adverse effects*
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels / antagonists & inhibitors
-
Ether-A-Go-Go Potassium Channels / metabolism
-
Evidence-Based Medicine
-
Heart Conduction System / drug effects*
-
Heart Conduction System / metabolism
-
Heart Conduction System / physiopathology
-
Humans
-
Long QT Syndrome / chemically induced*
-
Long QT Syndrome / metabolism
-
Long QT Syndrome / physiopathology
-
Potassium Channel Blockers / adverse effects
-
Quetiapine Fumarate
-
Risk Assessment
-
Risk Factors
-
Torsades de Pointes / chemically induced*
-
Torsades de Pointes / metabolism
-
Torsades de Pointes / physiopathology
Substances
-
Antipsychotic Agents
-
Dibenzothiazepines
-
ERG1 Potassium Channel
-
Ether-A-Go-Go Potassium Channels
-
Potassium Channel Blockers
-
Quetiapine Fumarate